Compare Estee Lauder Companies Inc (EL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Medpace Holdings Inc — how do they compare? Estee Lauder Companies Inc trades at $82.79 (market cap $29.78B), while Medpace Holdings Inc trades at $536.04 (market cap $15.11B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| EL | MEDP | |
|---|---|---|
Market Cap | $29.78B | $15.11B |
Sector | Consumer Staples | Technology |
52-Week High | $119.61 | $620.59 |
52-Week Low | $67.23 | $308.88 |
Enterprise Value | $35.95B | $14.58B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $82.72, up 2.3% with recent earnings beats but faces fundamental challenges including a negative net income margin of -1.67% and elevated P/E ratio of 147.8. Technical indicators show bearish momentum with support at $81 and resistance at $84. The company maintains strong gross margins at 74.71% and positive analyst sentiment with 44% buy ratings and $90.60 consensus target.
While recent earnings outperformance and strong brand positioning provide upside potential, investors face risks from declining revenue trends, negative profitability, and high valuation multiples. The stock's near-term direction will depend on Q2 2026 earnings delivery and management's ability to restore sustainable growth amid competitive pressures.
MEDP trades at $539.39, up 0.6% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue grew to $2.53B in 2025, and net income margins remain strong at 17.19%, though valuation ratios like P/E of 33.31 suggest premium pricing. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook: MEDP shows robust profitability and growth potential, but high valuations and legal risks warrant caution. Analyst consensus is mixed with a $497 price target below current levels, indicating limited upside. Key catalysts include Q2 2026 earnings on July 22, 2026, which could drive momentum if results exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
